Commercial Availability of Lutetium-177

By Biotechdaily staff writers
Posted on 06 Nov 2002
Lutetium-177 (Lu-177), an important radioisotope being investigated for use in the radiotherapeutic treatment of cancers such as breast, prostate, colon and brain, is now commercially available from PerkinElmer Life Sciences (Boston, MA, USA).

PerkinElmer says it is the first company with worldwide distribution capabilities to offer Lu-177. Until now, there has been no reliable supplier of this important radioisotope. Demand for Lu-177 is increasing, and the current commercial supply is limited. PerkinElmer's goal is to provide the market with a much-needed continuous and reliable supply. The company's broad distribution channels are geared to help ensure timely, quality delivery of this short-lived isotope. The product is available for research use only.

PerkinElmer is committed to accelerating the market development for this important radioisotope, which could lead to another treatment for cancer,” said Paul Gillyon, vice president and general manager of research products at PerkinElmer Life Sciences. "By making radionuclides like lutetium-177 and yttrium-90 available commercially, we believe we can support and impact research that will lead to newer and better therapeutic alternatives.”




Related Links:
PerkinElmer

Latest BioResearch News